Blab AI
NIMS and IISc Launch Joint AI Research Programme to Detect Cancer, Kidney and Heart Diseases Early
On Thursday, 17 June 2026, the Nizam’s Institute of Medical Sciences (NIMS) in Hyderabad and the Indian Institute of Science (IISc) in Bengaluru announced a new joint research programme that will harness artificial‑intelligence (AI) to spot breast cancer, oral cancer, kidney disease, cardiovascular disorders and obesity‑related conditions earlier than current methods allow.
The partnership was formalised during a visit by IISc scientists to NIMS, where NIMS Dean Dr P. Chandrasekhar outlined the project’s potential. He explained that AI‑powered tools could help clinicians diagnose the five target diseases more quickly and accurately, and that the collaboration would specifically tailor AI models to reflect the health profiles of Indian patients.
Both institutions set a clear research agenda: develop advanced AI models for diagnosis, risk assessment, disease‑progression analysis and personalised treatment planning across the five disease categories. The teams will draw on clinical data from NIMS to train and validate the algorithms, and aim to produce preliminary models within the first six months.
The meeting’s NIMS delegation—comprising Dr Chandrasekhar, Dr Liza, Dr Bhushan Raju, Dr Anu Kapoor, Dr Subbalakshmi, Dr Sujata Patnaik, Dr Ramakrishna, Dr Annie, Dr Raviteja and Dr Payal—worked alongside the IISc delegation of Dr Sriram, Dr Hema and Dr Anagha. Together they charted a roadmap that covers data‑collection protocols, algorithm design, and the steps needed to move from prototype to clinical validation.
During the first six‑month phase, the teams will analyse clinical data, design AI algorithms and build preliminary models. The goal is to deliver decision‑support tools that flag high‑risk patients early, enabling timely interventions and potentially improving outcomes.
This collaboration is part of a wider trend of public‑private research partnerships in India that aim to leverage AI for health. By combining NIMS’s clinical expertise and patient data with IISc’s research capabilities, the programme seeks to produce AI solutions that are both scientifically robust and clinically relevant.
A key emphasis of the partnership is the importance of tailoring AI models to local populations. Dr Chandrasekhar noted that disease prevalence, genetic factors and healthcare infrastructure in India differ from those in Western countries, and that models trained on international data may not perform optimally for Indian patients.
Although the project is still in its early stages, the joint effort is expected to generate a pipeline of AI tools that could be integrated into NIMS’s clinical workflow and eventually scaled to other hospitals across the country. Success will hinge on the quality of the data, the robustness of the algorithms and the ability to translate research findings into usable clinical applications.
In summary, the NIMS‑IISc joint research initiative is a focused effort to develop AI models for early detection and personalised management of breast cancer, oral cancer, kidney disease, cardiovascular disorders and obesity‑related conditions. The first six‑month phase will deliver preliminary models that can support clinicians in Hyderabad and beyond, with future work aimed at clinical validation, regulatory approval and broader deployment across Indian healthcare settings.
The partnership was formalised during a visit by IISc scientists to NIMS, where NIMS Dean Dr P. Chandrasekhar outlined the project’s potential. He explained that AI‑powered tools could help clinicians diagnose the five target diseases more quickly and accurately, and that the collaboration would specifically tailor AI models to reflect the health profiles of Indian patients.
Both institutions set a clear research agenda: develop advanced AI models for diagnosis, risk assessment, disease‑progression analysis and personalised treatment planning across the five disease categories. The teams will draw on clinical data from NIMS to train and validate the algorithms, and aim to produce preliminary models within the first six months.
The meeting’s NIMS delegation—comprising Dr Chandrasekhar, Dr Liza, Dr Bhushan Raju, Dr Anu Kapoor, Dr Subbalakshmi, Dr Sujata Patnaik, Dr Ramakrishna, Dr Annie, Dr Raviteja and Dr Payal—worked alongside the IISc delegation of Dr Sriram, Dr Hema and Dr Anagha. Together they charted a roadmap that covers data‑collection protocols, algorithm design, and the steps needed to move from prototype to clinical validation.
During the first six‑month phase, the teams will analyse clinical data, design AI algorithms and build preliminary models. The goal is to deliver decision‑support tools that flag high‑risk patients early, enabling timely interventions and potentially improving outcomes.
This collaboration is part of a wider trend of public‑private research partnerships in India that aim to leverage AI for health. By combining NIMS’s clinical expertise and patient data with IISc’s research capabilities, the programme seeks to produce AI solutions that are both scientifically robust and clinically relevant.
A key emphasis of the partnership is the importance of tailoring AI models to local populations. Dr Chandrasekhar noted that disease prevalence, genetic factors and healthcare infrastructure in India differ from those in Western countries, and that models trained on international data may not perform optimally for Indian patients.
Although the project is still in its early stages, the joint effort is expected to generate a pipeline of AI tools that could be integrated into NIMS’s clinical workflow and eventually scaled to other hospitals across the country. Success will hinge on the quality of the data, the robustness of the algorithms and the ability to translate research findings into usable clinical applications.
In summary, the NIMS‑IISc joint research initiative is a focused effort to develop AI models for early detection and personalised management of breast cancer, oral cancer, kidney disease, cardiovascular disorders and obesity‑related conditions. The first six‑month phase will deliver preliminary models that can support clinicians in Hyderabad and beyond, with future work aimed at clinical validation, regulatory approval and broader deployment across Indian healthcare settings.
